Sector
PharmaceuticalsOpen
₹95.49Prev. Close
₹94.98Turnover(Lac.)
₹2,825.34Day's High
₹98.7Day's Low
₹94.652 Week's High
₹107.5452 Week's Low
₹57.5Book Value
₹58.34Face Value
₹2Mkt Cap (₹ Cr.)
2,861.6P/E
28.33EPS
3.44Divi. Yield
0.82Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 58.71 | 58.71 | 58.71 | 58.71 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,552.62 | 1,447.84 | 1,331.56 | 1,201.72 |
Net Worth | 1,611.33 | 1,506.55 | 1,390.27 | 1,260.43 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 2,184.02 | 1,966.98 | 1,894.47 | 983.3 |
yoy growth (%) | 11.03 | 3.82 | 92.66 | 38.36 |
Raw materials | -1,570.51 | -1,102.84 | -1,065.01 | -695.28 |
As % of sales | 71.9 | 56.06 | 56.21 | 70.7 |
Employee costs | -141.3 | -115.55 | -97.2 | -56.1 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 236.77 | 571.39 | 533.24 | 31.3 |
Depreciation | -43.26 | -38.92 | -35.73 | -30.21 |
Tax paid | -57.18 | -126.83 | -171.95 | -3.6 |
Working capital | -112.32 | 268.04 | 207.28 | -4.75 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 11.03 | 3.82 | 92.66 | 38.36 |
Op profit growth | -56.69 | 3.12 | 362.95 | 21.29 |
EBIT growth | -57.54 | 4.15 | 479.37 | 29.94 |
Net profit growth | -62.73 | 23.04 | 1,204.29 | 493.14 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Gross Sales | 2,079.21 | 2,132.79 | 2,217.11 | 2,184.02 |
Excise Duty | 0 | 0 | 0 | 0 |
Net Sales | 2,079.21 | 2,132.79 | 2,217.11 | 2,184.02 |
Other Operating Income | 0 | 0 | 0 | 0 |
Other Income | 22.41 | 30.07 | 25.61 | 32.04 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Varinder Gupta
Non-Exec. & Independent Dir.
Sandhya Mehta
Joint Managing Director
Vikas Gupta
Chairman & Independent Directo
Rajender Mohan Malla
Non-Exec. & Independent Dir.
Harpal Singh
Company Sec. & Compli. Officer
Abhay Raj Singh
Director (Works)
Kushal Kumar Rana
Non-Exec. & Independent Dir.
SHARAD TYAGI
Executive Director
Abhiraj Gupta
Additional Director
Rajni Jha
Trident Complex,
Raikot Road Barnala,
Punjab - 148101
Tel: 91-01679-244701-07
Website: http://www.iolcp.com
Email: investor@iolcp.com; contact@iolcp.com
A-40 II Flr Phase-II,
Naraina Indl Area, Near Batra Banquet,
New Delhi - 110 028
Tel: 91-11-41410592/93/94
Website: www.linktime.co.in
Email: delhi@linkintime.co.in
Summary
IOL Chemicals and Pharmaceuticals Limited, incorporated in September, 1986 is a renowned company in the Active PharmaceuticalIngredient (API) and specialty chemicals sectors. With substantive manufact...
Read More
Reports by IOL Chemicals & Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.